CoChat

A potently neutralizing SARS-CoV-2 antibody inhibits variants of concern by utilizing unique binding residues in a highly conserved epitope

Open access
VanBlargan, Laura A., Adams, Lucas J., Liu, Zhuoming, Chen, Rita E., Gilchuk, Pavlo, Raju, Saravanan, Smith, Brittany K., Zhao, Haiyan, Case, James Brett, Winkler, Emma S., Whitener, Bradley M., Droit, Lindsay, Aziati, Ishmael D., Bricker, Traci L., Joshi, Astha, Shi, Pei-Yong, Creanga, Adrian, Pegu, Amarendra, Handley, Scott A., Wang, David, Boon, Adrianus C.M., Crowe, James E., Whelan, Sean P.J., Fremont, Daved H., Diamond, Michael S. · 2021 · Immunity
Cited by 94

The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.

Abstract

With the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants with increased transmissibility and potential resistance, antibodies and vaccines with broadly inhibitory activity are needed. Here, we developed a panel of neutralizing anti-SARS-CoV-2 monoclonal antibodies (mAbs) that bound the receptor binding domain of the spike protein at distinct epitopes and blocked virus attachment to its host receptor, human angiotensin converting enzyme-2 (hACE2). Although several potently neutralizing mAbs protected K18-hACE2 transgenic mice against infection caused by ancestral SARS-CoV-2 strains, others induced escape variants in vivo or lost neutralizing activity against emerging strains. One mAb, SARS2-38, potently neutralized all tested SARS-CoV-2 variants of concern and protected mice against challenge by multiple SARS-CoV-2 strains. Structural analysis showed that SARS2-38 engaged a conserved epitope proximal to the receptor binding motif. Thus, treatment with or induction of neutralizing antibodies that bind conserved spike epitopes may limit the loss of potency of therapies or vaccines against emerging SARS-CoV-2 variants.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.immuni.2021.08.016

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 43 references

Cited by

See all 94

Metadata

Authors
VanBlargan, L. A., Adams, L. J., Liu, Z., Chen, R. E., Gilchuk, P., Raju, S., Smith, B. K., Zhao, H., Case, J. B., Winkler, E. S., Whitener, B. M., Droit, L., Aziati, I. D., Bricker, T. L., Joshi, A., Shi, P.-Y., Creanga, A., Pegu, A., Handley, S. A., Wang, D., Boon, A. C. M., Crowe, J. E., Whelan, S. P. J., Fremont, D. H., & Diamond, M. S.
Venue
Immunity
Publisher
Elsevier BV
Published
2021-10
Volume
54
Issue
10
Pages
2399-2416.e6
ISSN
1074-7613 (ISSN-L)
OpenAlex
W3195351407
Cited by
94
References
43
FWCI
6.44
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A potently neutralizing SARS-CoV-2 antibody inhibits variants of concern by utilizing unique binding residues in a highly conserved epitope. https://app.cochat.ai/papers/10.1016/j.immuni.2021.08.016
The paper
VanBlargan, L. A., Adams, L. J., Liu, Z., Chen, R. E., Gilchuk, P., Raju, S., Smith, B. K., Zhao, H., Case, J. B., Winkler, E. S., Whitener, B. M., Droit, L., Aziati, I. D., Bricker, T. L., Joshi, A., Shi, P.-Y., Creanga, A., Pegu, A., Handley, S. A., . . . Diamond, M. S. (2021). A potently neutralizing SARS-CoV-2 antibody inhibits variants of concern by utilizing unique binding residues in a highly conserved epitope. Immunity. https://doi.org/10.1016/j.immuni.2021.08.016

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.